We have previously reported that alloreaction can lead to activation of dendritic cells through secretion of inflammatory cytokines. Here, we addressed whether alloreaction-derived cytokines may also lead to acute myelogenous leukemia (AML) blast differentiation. With this aim, supernatant (sn) harvested from major or minor histocompatibility antigen-mismatched mixed lymphocyte reaction (MLR) were used to culture French American Bristish (FAB) type M4 or M5 AML blasts. Our results showed that the secreted factors induced upregulation of CD40, CD54, and/or HLA molecules in AML blasts. Protein fractionation, blockade experiments and exogenous cytokine reconstitution demonstrated the involvement of TNF in the upregulation of CD54, CD40 and HLA-class II molecules, and of IFNc in the increase of HLA-class I and class II molecule expression. But, in line of its much higher levels of secretion, TNFb, rather than TNFa, was likely to play a preponderant role in AML blast differentiation. Moreover TNFb and IFNc were also likely to be involved in the AML blast differentiation-mediated by HLAidentical donor T-cell alloresponse against recipient AML blasts. In conclusion, we show herein that upon allogeneic reaction, TNFb secretion contributes, in concert with IFNc, to increase or restore surface molecules involved in AML blast interaction with T cells.
Introduction
Allogeneic bone marrow transplantation (BMT) is a therapeutic approach used to eradicate hematological malignancies, such as leukemias, [1] [2] or even solid tumors. 3 However, this treatment is associated with severe side effects, the most serious of which is graft-versus-host-disease (GVHD). 4 At present, the understanding of the effector mechanisms that trigger GVHD implicates both cell-mediated cytotoxicity against host tissues and inflammatory cytokines. Thus, the dissection of the patho-physiological mechanisms that are involved in GVHD demonstrates several sequential steps. [5] [6] [7] [8] [9] In the first phase, cytokines, such as TNFa, IL-1 and IL-6, are secreted during the conditioning regimen and contribute to activation of donor T cells. Subsequently, stimulation of donor T cells by host antigens in concert with the phase 1-secreted cytokines leads to production of cytokines, including, IL-2 and IFN-g, which amplify the allogeneic response and activate mononuclear phagocytes. The third phase involves secretion of inflammatory cytokines, such as IL-1 and TNFa, by these latter cells. These cytokines, in synergy with T and NK cell-mediated cytotoxicity, induce host tissue injury. Acute GVHD results in deleterious effects which target mostly skin, digestive tract, and liver. 10 Moreover, it has been reported in the latter disease stage, that release of lipopolysaccharide (LPS) by damaged epithelial tissues enhances effector functions of mononuclear phagocytes (for review see reference 11, 12 ). Prognosis would then depend on the disease stage. Like GVHD, graft-versus-leukemia (GVL) is known to principally result from cell-mediated cytotoxicity, but here the targets are leukemic cells, rather than host tissues. [13] [14] [15] [16] Thus, because GVHD facilitates GVL and due to the knowledge that leukemic cells of myeloid origin with monocytic components can differentiate into potent antigen presenting cells (APC), like dendritic cells, depending on the cytokine environment, [17] [18] [19] [20] we questioned here whether secretion of cytokines during GVHD could enhance the antigen presenting capacity of leukemic cells. To test this hypothesis, we performed in vitro allogeneic mixed leukocyte cultures, harvested supernatant (mixed leukocyte reaction (MLR-Sn)) and used them to culture acute myeloid leukaemia (AML) blasts from 10 patients with monocytic components, or AML blast cell lines. Their differentiation was evaluated by analyzing their cell surface phenotype.
Methods

Medium and reagents
RPMI 1640 (Life Technologies, Eggenstein, Germany) was supplemented with L-glutamin (2 mM), penicillin (100 U/ml), streptomycin (100 mg/ml), NaHCO 3 (1.5 mg/ml) and 10% of pooled human AB heat inactivated serum. In other experiments X-VIVO 20 (Bio-Whittaker, Walkersville, MD, USA) was used instead of RPMI 1640. In the latter case, neither serum nor antibiotics, NaHCO 3 , nor L-glutamine were added.
Patients
Ten patients with newly diagnosed acute myeloid leukemia were studied. Diagnosis was based on May-Grü nwald-Giemsa stained bone marrow smears and cytochemistry according to the French-British-American-Group criteria. Morphology and karyotypic characteristics of patients are shown in the table below. All patients gave written informed consent to the study according to French legislation. Here, are the characteristics of the patients, whose data are shown in this study.
Allogeneic MLR Supernatant production
Mononuclear cells (MNC) collected from healthy volunteer donors were irradiated at 30 Gy and used to stimulate MNC from HLA-DR mismatched donors. Responding MNC (1 Â 10 6 ) were then cocultured in 24-well plates with 1 Â 10 6 stimulating cells in a 2 ml final volume for 5 days. Sn from four to five different MLR performed among different blood donor pairs were collected and mixed in order to minimize individual variations, filtered on 0.22 mm filters and supplemented with 10% human serum and antibiotics. The pH was adjusted at 7.4 by NaHCO 3 addition. In some experiments, MLR were performed in X-VIVO 20. In that case, MLR-Sn was not supplemented with serum. When HLA-identical MLR were performed, HLA-identical sibling pairs were used.
AML blasts harvest
FAB type M4 or M5 were harvested from blood or from bone marrow of patients, by using a ficoll density gradient. Cells were then separated by using CD34-coated magnetic beads from Myltenyi (Miltenyi Biotec, Paris, France), according to manufacturer's instructions. Purity was higher than 95%, as assessed by cytofluorometric analysis of labelled cells.
AML blast culture in MLR-Sn
Purified AML blasts were then cultured in MLR-Sn for four days. With this aim, MLR-Sn was supplemented with 10% HS, L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 mg/ ml), and NaHCO 3 (1.5 mg/ml), except when MLR-Sn was harvested from X-VIVO 20 cultures. At day 3, half of the medium was discarded and replaced with fresh MLR-Sn. As control, AML blasts were cultured in the absence of MLR-Sn. At day 4, cells were collected and analyzed.
Neutralizing antibodies
MLR-Sn was neutralized for its cytokine content by addition of blocking antibodies directed against IL-1b, IFN-g (Immunotech, Marseille, France), IL-6 (PeproTech, Rocky Hill, NJ, USA), IL-8 (R&D Systems) and TNFa (R&D Systems). MLR-Sn cytokine deprivation was then evaluated by enzyme linked immunosorbent assay (ELISA).
Cytofluorometric analyses
Cell surface staining was performed using FITC-or PEconjugated and affinity purified mouse monoclonal antibodies. Analyses were performed using a FACScan flow cytometer and the CellQuest software (BD, Erembodegem-Aalst, Belgium). The following monoclonal antibodies (mAbs) were purchased from BD: anti-CD54, anti-CD80, anti-CD86 and anti-HLA. The anti-CD40 mAbs were purchased from Immunotech (Marseille, France). Isotypic controls included IgG 1 , IgG 2a and IgG 2b (BD).
Cytokine measurement assays
Cytokine concentrations were evaluated by standard commercially available ELISA according to manufacturer instructions. IL-2, IL-4, IL-10 and IFN-g ELISA kits were purchased from Biosource (Nivelle, Belgium), IL-1b, IL-6 and TNFa were from R&D Systems (Abingdon, UK). TNF activity was measured by using a biological assay, using Wehi 1640 clone 13 cells murine fibrosarcoma, obtained through the courtesy of P van der Bruggen (Ludwig Institute for Cancer Research, Brussels, Belgium). The assay was performed as described, in the presence of LiCl, to optimize sensitivity to TNF-mediated cytotoxicity and using a tetrazolium-based colorimetric assay to estimate mortality of WEHI cells. Briefly, apropriate sample dilutions were incubated with 30 000 cells in a final volume of 100 ml RPMI 1640 medium suplemeneted with 5% FCS, 10 mM HEPES, L-arginine (116 mg/l), L-asparagine (36 mg/l), L-glutamine (216 mg/l) and 20 mM LiCl. Cell viability was measured after 20 h using Promega's CellTiter 96 TM MTS assay (Promega Corporation). The respective contribution of TNFb orTNFa to Wehi mortality was determined by adding specific anti-beta or anti-alpha mAbs (R&D Systems) to the samples before incubation with Wehi cells.
Treatment of MLR-conditioned medium with proteinase K Sn 19 (200 ml) was treated for 15 h at 371C with proteinase K (0.3 mg/ml) after addition of Tris-HCl pH 8.5 (final concentration 0.17 M) and EDTA (4 mM). The reaction was stopped by addition of 10 ml PefablocSC (Boehringer Mannheim, Germany) and transferred to PBS by ultrafiltration (Ultrafree 5000, Millipore, Molsheim, France).
Size exclusion chromatography
Five hundred microliters of 10 fold concentrated MLR-Sn was fractionated at 0.5 ml/minon a Superose 12 column (Amersham Pharmacia Biotech, Buckinghamshire, England) equilibrated in phosphate-buffered saline (PBS). Fractions of 0.5 ml were collected.
Results
MLR-Sn harvested from full HLA mismatched MLR enhances expression of CD54, CD40 and/or HLA molecules on AML blast
To investigate leukemic cell differentiation, secondary to an alloreaction, CD34 þ cells from FAB type M4 or M5 AML blast were purified using magnetic beads to reach a purity of at least 85% and were then cultured with MLR-Sn, or as negative control, with medium containing 10% human serum. Following 4 days of culture, AML blast immunophenotype was determined by cytofluorometry, using antibodies directed against molecules involved in antigen presentation and/or T cell co-activation. Figure 1 shows the results obtained with AML blasts harvested Abbreviations: AML, acute myeloid leukemia; HLA-DR, human leukocyte antigen; MF1, mean flurosence intensity; MLR-Su, mixed lymphocyte reaction-supernatant. AML blasts from seven patients, or from three AML cell lines, named HL60, U937 and K6-1 were cultured for 4 days in either complete culture medium, or MLR-Sn harvested from HLA-DR mismatched MLR cultures, and were analyzed for expression of surface markers by cytofluorometry.
CD40, CD54 and/or HLA molecule expression A Eljaafari et al from three different patients, named no. A, B and C. AML blasts cultured in MLR-Sn clearly acquired significant degree of differentiation. In those from patients no. A and B, the expression of CD54, CD40, HLA-class II and HLA-class I molecules were upregulated, whereas in those from patient no. C, only some of these molecules significantly increased, such as CD54 and HLA class I. However, there was no significant upregulation of B7-1 (CD80) nor B7-2 (CD86) molecules. These results are characteristic of those obtained from the AML blasts of seven other patients, and from three AML cell lines (see Table 1 ). Indeed, in every case, we observed an upregulation of HLA, co-activation and/or co-stimulatory molecule expression, which was attested either by an increase of the percentage of positive cells, the mean fluorescence intensity (MFI), or both.
Alloreactivity against HLA-identical sex-mismatched APCs or AML blasts can also lead to AML blast differentiation
We then investigated the effect of Sn collected from HLAidentical MLR on AML blast differentiation. With this aim, Sn was produced from MLR performed between HLA-identical CD40 Table 2 show some variable and moderate effects of HLA-identical MLR-Sn on AML blast differentiation. However, when an HLA-identical pair, which has been used previously to generate HY-specific T-cell clones, 21 was used to produce MLR-Sn, we observed that Sn collected from secondary MLR resulted in a marked increase of costimulatory and HLA molecule expression, which levels were comparable to that induced by HLA-DR mismatched MLR-Sn, provided that the MLR was performed in the HY-mismatched direction, but not reciprocally. These results suggest thus a role for minor histocompatibility-Ag induced allo-reactivity on AML last differentiation.
As a result of HLA-identical bone marrow transplantation host leukemic cells can be targeted by donor T cells, we then asked whether this allo-reactivity could induce modification of AML blast phenotype. To answer this question, we harvested HLAidentical T cells from the sibling donor of patient D and cultured them in the presence of recipient AML blasts, for 5 days. MLR-Sn was then collected and used to culture the AML blasts. As control, AML blasts were cultured either with autologous MLRSn or with HLA-DR mismatched MLR-Sn. Results shown in Figure 2 demonstrate that this allo-reactivity was able to induce a marked differentiation of patient D AML blasts. When two other HLA-identical MLR-Sn obtained from MLR performed Table 3 Cytokine content of MLR-Sn In part 2, cytokine secretion was measured in MLR-Sn harvested from an HLA-identical MLR that was performed among a sibling pair, in which AML blasts were used as stimulators. Secretion of cytokines from autologous MLR-Sn was also measured as control. CD40, CD54 and/or HLA molecule expression A Eljaafari et al between sibling donor-recipient pairs were tested, we observed a significant differentiation of AML blasts in one of the two AML blasts, but at a lesser extend than the data shown in Figure 2 (not shown). Thus, these results suggest that HLA-identical alloreactivity against AML blasts can result in AML blast differentiation, through secretion of soluble factors.
Cytokine profile of MLR-Sn
We then addressed whether the proinflammatory cytokines IL-1, TNFa, IFNg, IL-6 and IL-2 that have been described by others to participate into the GVHD-mediated host tissue damage, 8 were also present in major or minor histocompatibility mismatched MLR-Sn. Results shown in Table 3 , indicated that high levels of IL-1, TNFa, IFNg and IL-6 were still present at day 5 of culture, when MLR-Sn were harvested. However, IL-2 was not detected, which might result from its consumption by day 5. Interestingly, in the Sn harvested from the MLR performed between sibling donor HLA-identical T cells and patient D AML blasts, only IFNg secretion was significantly increased, suggesting thus the possibility that, in addition to IFNg, another cytokine, different from TNFa, IL-1, and IL-6, might be involved in this differentiation process. As control, autologous MLR did not lead to any significant levels of cytokine secretion. (Table 3 , expt no. 3 panel).
Upregulation of CD40 and HLA class I, but not CD54 and HLA class II molecule by MLR-Sn is inhibited by antibodies directed against IL-1, IL-6, IFNg and TNFa
We then further investigated whether IL-1, IL-6, TNFa and IFNg the cytokines known to contribute to the development of the lesions observed during GVHD, could be those, which are implicated in differentiation of AML blasts.
To answer this question, neutralizing antibodies directed against each of these cytokines were added to MLR-Sn, before AML blast culture. These Abs were added either alone or in concert. As shown in the last lane of Table 3 , exp no. 1 panel, the neutralization of these cytokines was almost complete. AML blasts from patient no. D were then used to investigate the effects of inflammatory cytokine deprivation from MLR-Sn. As shown in Figure 3 , in AML blasts cultured with MLR-Sn deprived from TNFa, IFNg, IL-1 and IL-6, neither HLA class II or CD54 expression was significantly affected by the neutralization of Figure 4 Fractionation of MLR-Sn by size chromatography and analysis of the effect of each fraction of AML blasts phenotype. MLR-Sn was fractionated by size exclusion chromatography. Then, each fraction was used to culture AML blasts for 4 days. Cytofluorometric analyses were used to evaluate the effect of the fractions on AML blast differentiation. In parallel, TNF activity was measured by using a biological assay, as described in Materials and methods.
CD40, CD54 and/or HLA molecule expression A Eljaafari et al these cytokines. In contrast, enhancement of HLA-class I molecule expression was predominantly impaired by anti-IFNg mAb alone, while upregulation of CD40 expression was partially inhibited in the presence of anti-IFNg, plus anti-IL-1, anti-IL6 and anti-TNFa Ab, indicating thus that the expression of HLA class I and CD40 molecules was dependent, at least in part, on these inflammatory cytokines.
The soluble factor(s) present in MLR-Sn and responsible for blast differentation is (are)( a) protein(s) ranging from 75 to 60 kDa in size
In order to avoid interference by serum during purification of the factor(s) involved in blast differentiation, MLR was performed in X-VIVO 20 serum-free medium. Sn was collected and used to culture AML blasts, which acquired the same phenotype than that obtained in the presence of MLR-Sn and 10% human serum (not shown). Treatment of this MLR-Sn with proteinase K abolished its AML blast differentiation activity (data not shown). We therefore started to characterize the protein(s) responsible for blast differentiation by size exclusion chromatography. Culture of AML blasts from patient no. D with proteins ranging from 60 to 75 kD in size (fractions 12-15) resulted in a marked upregulation of CD54, and HLA class II molecule expression, but only in a weak increase of HLA-class I and CD40 molecule expression (Figure 4 ). These fractions corresponded to the elution profile of the TNF activity of MLR-Sn (Figure 4 , lower panel).
TNFb plays a preponderant role in MLR-Sn mediated AML blast differentiation, relative to its high level of secretion We then measured TNFa and TNFb activities in various HLAmismatched MLR-Sn (no. [4] [5] [6] and in MLR-Sn no. 7 and 8 harvested from an MLR performed between HLA-identical donor T cells and recipient AML blasts. We observed that TNFb was responsible for most of the TNF bioactivity present in these media, except in MLR-Sn no. 7 where TNFa and TNFb were secreted at almost similar levels ( Figure 5 ). We therefore used anti-TNFb Ab to analyse the contribution of this factor to the effect of MLR-Sn on AML blasts. In accordance to results shown in Figure 3 , addition of a pool of antibodies directed against IFNg, TNFa, IL-1, plus IL6, significantly inhibited CD40 and HLA class I molecule expression, but not HLA-class II or CD54. However, when anti-TNFb mAb was added in conjunction with anti-TNFa, anti-IFNg, anti-IL-6 and anti-IL-1, a strong inhibition of MLR-Sn-mediated AML blast differentiation was observed ( Figure 6 ).
Exogenous IFNg and TNFb act in concert to induce AML blast differentiation
We then investigated the precise biological effects of IFNg and TNFb cytokines on AML blast differentiation, by culturing AML blasts with the relevant cytokines. As shown in Table 4 , exogenous TNFb increased the expression levels of HLA class II, CD54 and CD40 molecules, but only weakly those of HLA class I molecules. IFNg preponderantly increased HLA class I and class II molecules, but had no or only low effect on CD40 and CD54 molecule expression, respectively. However, the concerted action of IFNg and TNFb resulted in the complete recovery of the phenotype induced by MLR-Sn. Exogenous TNFa CD40, CD54 and/or HLA molecule expression A Eljaafari et al had similar effects on AML blast differentiation than TNFb, which was expected since these cytokines have almost similar biological effects, even though they are differentially secreted.
Discussion
In this study, we have shown that cytokines secreted upon allogeneic reaction are able to modify the phenotype of AML blasts. Indeed, among 10 patients with FAB type 4 or 5 AML, we have observed an increased expression of several molecules known to be implicated in antigen presentation to T cells. Those molecules were either (i) HLA-DR, -DQ, or -class I products involved in antigenic peptide presentation, (ii) ICAM-1 molecules implicated in adhesion of T cells to antigen presenting cells or (iii) CD40 molecules which co-activate T cells. No increase of B-7, that is: CD80 or CD86, molecules, two potent costimulatory molecules were observed. Various AML cell lines, such as HL-60, U937 and K6-1 were also cultured with MLR-Sn. Among these AML cell lines, HL-60 does not express HLA class I and class II, at the basal level. Interestingly, we observed that MLR-Sn was able to restore expression of HLA-class I molecules in HL-60, together with increased expression of CD54 and CD40 molecules. The effect of MLR-Sn on K6-1 resulted in increased expression of CD54, HLA class I and class II molecules, and U937 showed increased expression of CD54 and HLA-class I molecules (Table 1) . Therefore, those result strongly support the data obtained with fresh AML blasts. We also observed that MLR-Sn collected from primary MLR performed between AML blasts and sibling donor HLA-identical T cells resulted in AML blast differentiation (Figure 2 ), which suggests therefore that alloreactivity against minor histocompatibility Ag could lead to AML blast differentiation, through secretion of cytokines. However, an addititive possibility could be that the effect of HLA-identical MLR-Sn on AML blast differentiation is related to reactivity against leukemic antigens, instead of minor histocompatibility antigens. While we were not able to test the effect on AML blast differentiation of recipient autologous response, due to insufficient amounts of purified recipient T cells, we have tested the possibility that minorhistocompatibility Ag could induce AML blast differentiation. This was achieved by performing a MLR among a sex-gendermismatched healthy blood donor sibling pair, which has been previously reported by us, as able to lead to H-Y specific T-cell clone generation. 21 The Sn harvested from this HLA-identical sex-gender mismatched MLR was able to induce some differentiation of patient D AML blasts, which improved even more when Sn was collected from secondary, instead of primary, HLA-identical MLR (Table 2) . Interstingly, in the nonsex gender mismatched direction, no significant differentiation of AML blasts was observed, even when using the secondary MLR-Sn. Thus, these results suggest an effect of soluble factors secreted upon minor-histocompatibility-Ag-mediated alloresponse on AML blast differentiation. But this effect was strongly significant specially with secondary MLR, which was not the case when AML blasts were used as APC. Therefore either minor-histocompatibility-Ag or AML blast Ag might be involved in AML blast differentiation.
AML blasts have been shown to differentiate into dendritic cells in the presence of cytokines, like GM-CSF, IL-4 and TNFa, resulting in most cases in increased expression of several molecules including B 7-1 and B 7-2; 17, 18 However, this did not occur in our study since these latter two molecules never significantly increased. Thus, it seems unlikely that the differentiated AML blasts that we obtained are dendritic cells.
We then analyzed the cytokine content of the allogeneic reaction Sn. Cytokines known to participate into GVHDmediated host tissue damages, such as IL-1, TNFa, IFNg and IL-6 were expressed in HLA-mismatched MLR-Sn. IL-2 was not present due to its probable consumption. Indeed, MLR-Sn was harvested at day 5 of culture, because it was the most efficient at this period (data not shown). Interestingly, those cytokines were likely to play a role in CD40 and HLA class I upregulation, since neutralizing them with a combination of antibodies directed against each of them resulted in decreasing or abrogating the MLR-Sn-mediated effect on these two molecules, respectively ( Figure 3) . In agreement, a previous study has reported that treatment of AML blasts with IFNg results in increase of HLA class I expression. 22 In contrast, CD54 and HLA class II molecules appeared to be upregulated in the absence of IL1, IL-6, IFNg and TNFa, as suggested by results shown in Figure 3 . Thus, together, these results strongly suggest that CD40 and HLA-class I, on the one hand, CD54 and HLA-class II molecules on the other hand, are differentially regulated by the soluble factors that are present in allogeneic reaction Sn. Moreover, our results also suggest that B-7 molecules are independently regulated. We then used proteinase K to investigate whether the soluble factors, which were responsible for the differentiating effect of MLR-Sn on AML blasts were proteins. This was indeed the case, as assessed by the inhibitory effect of proteolysis (not shown). Fractionation of the allogenic Sn by size exclusion chromatography demonstrated that essential Table 4 IFNg and TNFa or b are able to mimick the effect of MLR-Sn on blast phenotype MLR-Sn activity relied on proteins ranging from 60 to 75 KD in size and coincided with that of TNF activity (Figure 4) . However, anti-TNFa failed to abrogate AML blast differentiation induced by MLR-Sn (Figure 3) , which suggested the involvement of TNFb rather, or in addition to, TNFa. We therefore used antiTNFb mAb to analyse the contribution of this factor and observed a strong inhibition of the effect of MLR-Sn on AML blast differentiation, when anti-TNFb was added together with Abs directed against proinflammatory cytokines. Like TNFa, TNFb, also named lymphotoxin A, is a protein that can trimerize to form complexes 23, 24 and that binds to the same TNF receptor. But, TNFa, rather than TNFb has been shown to be involved in the pathophysiological events leading to GVHD. As TNFb is preponderantly secreted by lymphocytes, 25 the differential deleterious effect of TNF on GVHD could result from high levels of TNFa secretion by monocytes/macrophages due to the pretransplantation conditioning regimen. 12 Another possibility could be that TNFa exerts superior cytotoxicity and proinflammatory activity, due to its superior capacity to activate the nuclear factor kB, subsequently to its conformation. 26, 27 Here, we have shown that allogeneic reaction leads to much higher levels of TNFb secretion than TNFa. Moreover, we have observed that MLR-Sn collected from AML blasts cultured with sibling donor HLA-identical T cells, leads to TNFb but not TNFa secretion. Thus, our results suggest that T-cell derived TNFb, more likely than TNFa, might contribute to the beneficial effects of alloreactivity on blast differentiation and recognition by T cells, leading thus to a potential GVL effect. Thus, treatment of bone marrow transplanted patients with specific anti-TNFa mAb in order to prevent the deleterious GVHD effects 28, 29 could be a promising option, since it would reduce the extent of GVHD by diminishing the major component of conditioning-mediated effect on GVHD, which is the cytokine storm-secreted TNFa, but would retain a possible GVL effect, by preserving TNFb.
In conclusion, in addition to our previous report showing that alloreaction can lead to activation of dendritic cells through secretion of proinflammatory cytokines, like TNFa, IL-6, IL-1 and IFNg, 30 we show here that alloreaction can also lead to upregulation of HLA and accessory molecule expression on AML blasts, with a preponderant role for TNFb, in concert with IFNg. Therefore, determination of TNFb and IFNg production by donor T cells, in response to AML blast stimulation, could be used to select optimal bone marrow donors, since this could suggest a possible mechanism that leads to the GVL effect in vivo.
